Alice Valder Curran
Alice Valder Curran translates legal requirements into operational practices for clients in the health and life sciences industries. She focuses on manufacturer price reporting and compliance obligations under the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) 340B Drug Pricing Program. She has a deep understanding of the mechanics of average manufacturer price (AMP), BP, ASP, and 340B calculations.
Alice is equally comfortable working with commercial and finance personnel on compliance strategies or explaining to C-Suite executives the government pricing (GP) implications of common commercial strategies, and the strategic role that these programs can play for certain drugs. She teams with her white collar colleagues on GP-related enforcement matters, often taking the lead when interacting with enforcement authorities on the specifics of Medicaid, Medicare, and 340B programs.
Alice counsels pharmaceutical companies on the treatment of various commercial strategies in the government pricing calculations — from wholesaler, GPO, and managed care proposals, to product launch strategies and patient programs. Working with manufacturers of all sizes and maturities, Alice brings valuable insight on the strengths and weaknesses of commercialization trends across the industry. Alice develops GP policy documents, "reasonable assumptions" in support of calculation methodologies, and Centers for Medicare and Medicaid Services (CMS) and HRSA 340B recalculation disclosure submissions.
Policy advocacy rounds out Alice's practice. Her knowledge of these programs and how they impact a manufacturer's day-to-day operations, as well as its strategic interests, make Alice a sought-after resource for evaluating legislative and policy proposals. She also represents manufacturers directly before CMS and HRSA on general policy issues, as well as advocating for company-specific actions.
Areas of Focus
Successfully advocated to DOJ that it accept a manufacturer's routine restatement of Medicaid pricing data in lieu of pursuing an FCA matter.
Successfully advocated to HRSA that two categories of long-standing policy guidance were nonbinding on manufacturers.
Convinced CMS that certain products were entitled to new and distinct baseline AMPs because of their differences from prior, related products.
Supported a successful manufacturer audit of a 340B-covered entity suspected of diversion and duplicate discounts.
Supported policy advocacy efforts with CMS regarding the treatment of value-based pricing arrangements under the AMP/BP/ASP reporting requirements.
Advised manufacturers regarding limited distribution arrangements under the 340B Drug Pricing Program.
Coordinated review of launch strategies and associated commercial contracts and patient programs for multiple new product launches.
Advised manufacturers regarding 340B ceiling price restatement obligations and refunds to covered entities.
Latest thinking and events
18 November 2016